Topical All-trans Retinoic Acid Does not Influence Minimal Erythema Doses for UVB Light in Normal Skin

Sir,

Retinoids are used in several skin disorders, such as acne, psoriasis and ichthyoses. It is well established that retinoids interfere with epidermal proliferation (1, 2), keratinization (3) and inflammation control (4). Retinoids influence UV-induced skin changes (5). Topical all-trans retinoic acid (RA) improves photodamaged skin (5, 6).

Parallel with the therapeutic effect, topical retinoids often cause irritation, with erythema and some scaling (7). Although the irritant effect is probably not involved in the therapeutic action of retinoids, it is possible that the irritation property of all-trans RA could be, in part, accountable for some therapeutic effects (1, 7).

In this study we would like to challenge the common belief that topical retinoids enhance UV-induced inflammation. We therefore evaluated the minimal erythema dose (MED) for UVB irradiation on topical all-trans RA (tretinoin cream 0.05%), which is a frequently used clinical concentration, for 10 days. An area of the same size on the upper part of one leg was treated twice daily with the vehicle of tretinoin cream (per 100 g: cremor cetomacrogolis 88 g, alcohol ketonatus 12 g and butylhydroxytolueen 40 mg) also twice daily and for 10 days. The application of both creams on the legs was selected at random and was applied in a double-blind manner. From the beginning of the application, until 4 days after the last application of the creams the volunteers were instructed to avoid sunlight exposure and not to wash the area to which the cream was applied for at least 1 h after each application.

On day 8 of treatment, irradiation of the skin was performed in 12 evaluable subjects in order to determine the MED with 3 series of 6 increasing intensities of UVB light related to the skin type of the subjects: 1 series on the all-trans RA cream pre-treated skin, 1 on the vehicle cream pre-treated skin and untreated skin. The degree of erythema at different times before and after UVB irradiation was scored in the 3 different areas.

The following questions were addressed: (i) To what extent does a 7-day treatment of normal skin with all-trans RA 0.05% in its vehicle or its vehicle alone induce erythema? (ii) To what extent do these creams influence the MED for UV-B irradiation? (iii) What are the dynamics of erythema 24 and 48 h after UVB irradiation in all-trans RA pre-treated skin, vehicle pre-treated skin and untreated skin?

REFERENCES


Accepted August 16, 1999.

Masao Fukuzawa 1,2 and Toshiaki Saida 2
1Department of Dermatology, Suwa Red Cross Hospital and 2Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan.

MATERIALS AND METHODS

The study was a single-centre, double-blind, placebo-controlled study. Approval of the Ethics Committee was obtained. A total of 15 healthy volunteers (8 men, 7 women) participated in the study. The mean age was 25 years (range 21 – 30 years). Their skin types were varying from type I to type III according to Fitzpatrick’s classification (8).

An area of 8 x 20 cm on the ventral upper part of one leg was treated twice daily with all-trans RA (tretinoin cream 0.05%), which is a frequently used clinical concentration, for 10 days. An area of the same size on the upper part of the other leg was treated with the vehicle of tretinoin cream (per 100 g: cremor cetomacrogolis 88 g, alcohol ketonatus 12 g and butylhydroxytolueen 40 mg) also twice daily and for 10 days. The application of both creams on the legs was selected at random and was applied in a double-blind manner. From the beginning of the application, until 4 days after the last application of the creams the volunteers were instructed to avoid sunlight exposure and not to wash the area to which the cream was applied for at least 1 h after each application.

On day 8 of treatment, irradiation of the skin was performed in 12 evaluable subjects in order to determine the MED with 3 series of 6 increasing intensities of UVB light related to the skin type of the subjects: 1 series on the all-trans RA cream pre-treated skin, 1 on the vehicle cream pre-treated skin and 1 on non-treated skin on the lateral side of the upper part of one leg. Each dose was given to a piece of skin of 4 cm2. For UVB irradiation, UV21 lamps were used.

Before irradiation on days 8, 9 and 10 the skin was examined for erythema by visual scoring. The MED was defined as the lowest UVB dose that caused a distinct erythema with sharp margins over the irradiated area 24 h after irradiation. For erythema the following scale was used: 0 = no erythema; 1 = weak erythema; 2 = moderate
seen with other irritants, e.g., glycolic acid (13). These 2
areas. This perifollicular pattern may be related to the actions
demonstrated by the perifollicular erythema. UVB-induced erythema showed a diffuse erythema,
but (especially all-trans RA) cream-induced erythema
between cream-induced erythema and UVB-induced ery-
thema. UVB-induced erythema showed a diffuse erythema,
while (especially all-trans RA) cream-induced erythema
showed a marked erythema restricted to the perifollicular
areas. This perifollicular pattern may be related to the actions
of all-trans RA on the pilosebaceous duct and can also be
seen with other irritants, e.g., glycolic acid (13). These 2
distinct patterns of erythema permitted us to score both
parameters independently and separately.

The present study shows that topical treatment with all-
trans RA does not influence the response to a single exposure
to UVB light and does not change the MED.

RESULTS AND DISCUSSIONS

Previous studies showed that erythema induced by topically
applied retinoids is frequently seen during the first weeks of
treatment and usually subsides with continued treatment. This
erythematous reaction is clinically similar to a mild irritant
dermatitis (9) and therefore is designated also as 'retinoid
dermatitis' (10). In this study the Wilcoxon matched-pairs
signed-ranks test showed a significant difference (p < 0.01) betwenn all-trans RA cream and its vehicle with respect to the
induction of erythema (skin irritation) before UVB irradiation
and therefore this study reconfirms the irritative effect of all-
trans RA following twice daily applications during 7 days.

Dermatologists tend to avoid all-trans RA applications in
conjunction with UV exposure in order to avoid additive
irritation. Some studies investigated the relationship between
pre-treatment with all-trans RA and UVB irradiation,
regarding this expected additive irritation or intensity of
erythema (11, 12). However, no data are shown about the
question whether all-trans RA can influence the value of the
MED for UVB light itself.

The present study showed no significant difference
(p < 0.05) as to MED values either 24 or 48 h after UVB
irradiation between the all-trans RA cream treated skin, the
vehicle cream treated skin and untreated skin (Fig.1) using the
ANOVA test. When looking at the relationship between skin
type and MED value a significant higher MED value was
found in skin type 3 vs. skin type 1 and 2 (p < 0.01).

As both all-trans RA cream and the vehicle cream itself in
itself can induce erythema of the skin, it might be difficult to grade
post UVB irradiation erythema in retinoid-treated areas. However, a marked difference was found in erythema pattern
between cream-induced erythema and UVB-induced ery-
thema. UVB-induced erythema showed a diffuse erythema,
while (especially all-trans RA) cream-induced erythema
showed a marked erythema restricted to the perifollicular
areas. This perifollicular pattern may be related to the actions
of all-trans RA on the pilosebaceous duct and can also be
seen with other irritants, e.g., glycolic acid (13). These 2

Fig. 1. Minimal erythema doses (mean ± SEM) for UVB light at
test areas treated with all-trans retinoic acid (RA), vehicle and
untreated skin 24 and 48 hours after irradiation.
erythema; and 3 = strong erythema. Visual scoring occurred under
similar conditions of light and temperature.

REFERENCES

1. Marks R, Hill S, Barton SP. The effects of an abrasive agent on
normal skin and on photoaged skin in comparison with topical
2. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterisation of
intercellular adhesion molecule-1 (ICAM-1) and HLA-DR in
normal and inflamed skin: Modulation by recombinant gamma-
3. Fry L, MacDonald A, McMinn RM. Effects of retinoic acid in
4. Bradshaw D, Cashin CH, Kennedy AJ. Anti-inflammatory effects
of the retinoids. In: Cunliffe WJ, Miller AJ (eds.). Retinoid
5. Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin
6. Griffiths CEM, Goldfarb MT, Finkel LJ, Roulia V, Bonavietz M,
Hamilton TA, et al. Topical tretinoin (retinoic acid) treatment of
hyperpigmented lesions associated with photoaging in Chinese
and Japanese patients: a vehicle-controlled trial. J Am Acad
7. Fullerton A, Serup J. Characterisation of irritant patch test
reactions to topical D vitamins and all-trans retinoic acid in
comparison with sodium lauryl sulphate. Evaluation by clinical
scoring and multiparameter non-invasive measuring techniques.
8. Madhu P, Nghiem P, Fitzpatrick TB. Acute and chronic effects of
the sun. In: Freedberg I, Eisen AZ, Wolff K, Austen KF,
Goldsmith LA, Katz SI, et al. Fitzpatrick’s dermatology in
9. Fisher GJ, Esmann J, Griffiths CEM, Talwar HS, Duell EA,
Hammerberg C, et al. Cellular, immunologic and biochemical
characterisation of topical retinoic acid-treated human skin.
10. Shalita A, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz
HI, et al. A comparison of the efficacy and safety of adapalene gel
0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a
11. Juhlin L, Shroot B. Intensity and area increase of UVB-induced
erythema: two variables used for studies of the influence of
12. Meunier L, Voorhees JJ, Cooper KD. In vivo retinoid acid
modulates expression of the class II major histocompatibility
complex and function of antigen-presenting macrophages and
keratinocytes in ultraviolet-exposed human skin. J Invest
13. Effendy I, Kwangsukstith C, Lee JY, Maibach HI. Functional
changes in human stratum corneum induced by topical glycolic acid:
comparison with all-trans retinoic acid. Acta Derm Venereol

Accepted August 10, 1999.

J. V. Smit, E. M. G. J. de Jong, G. J. de Jongh and P. C. M. van de
Kerkhof
Department of Dermatology, University Hospital Nijmegen,
PO Box 9101, 6500 HB Nijmegen, The Netherlands.
E-mail: j.smit@derma.azn.nl

Acta Derm Venereol 80